Core Viewpoint - AstraZeneca's former China president, Leon Wang, has been formally prosecuted for insurance fraud and smuggling after over a year of investigation, marking a significant development in the company's ongoing legal challenges in China [2][3][4]. Group 1: Legal Issues - Leon Wang has been charged with illegal importation of drugs, illegal collection of personal information, and medical insurance fraud [3][4]. - The Shenzhen People's Procuratorate has completed its review, and both Wang and another former senior employee are facing formal criminal charges [4][6]. - AstraZeneca has confirmed that the charges against Wang relate to illegal activities, but the company has not disclosed specific names in its annual report [5][10]. Group 2: Company Performance and Impact - In 2024, AstraZeneca achieved a revenue of $54.073 billion, with China contributing a record $6.413 billion, reflecting an 11% year-on-year growth [8]. - The company has faced scrutiny due to ongoing investigations, including a previous insurance fraud case and allegations of smuggling [9][10]. - AstraZeneca has committed to investing over 100 billion RMB (approximately $15 billion) in China by 2030, indicating a strong long-term commitment to the market despite current challenges [12][13]. Group 3: Organizational Changes - Following Wang's investigation, AstraZeneca has initiated organizational restructuring in China, appointing Iskra Reic as the new global executive vice president responsible for international business [12]. - The company has accelerated its investment in China, including the opening of a new global strategic R&D center in Beijing [12][13]. - AstraZeneca's employee base in China is expected to exceed 20,000, representing about 20% of its total workforce [12].